These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28133814)

  • 1. Identification and specificity of broadly neutralizing antibodies against HIV.
    McCoy LE; Burton DR
    Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
    Moore PL; Gorman J; Doria-Rose NA; Morris L
    Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native-like Env trimers as a platform for HIV-1 vaccine design.
    Sanders RW; Moore JP
    Immunol Rev; 2017 Jan; 275(1):161-182. PubMed ID: 28133806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 envelope glycoprotein structure: nailing down a moving target.
    Ward AB; Wilson IA
    Immunol Rev; 2017 Jan; 275(1):21-32. PubMed ID: 28133813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
    Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
    Burton DR; Hangartner L
    Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host controls of HIV broadly neutralizing antibody development.
    Kelsoe G; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
    Andrabi R; Bhiman JN; Burton DR
    Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
    Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
    J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivors Remorse: antibody-mediated protection against HIV-1.
    Lewis GK; Pazgier M; DeVico AL
    Immunol Rev; 2017 Jan; 275(1):271-284. PubMed ID: 28133809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germinal center enhancement by extended antigen availability.
    Cirelli KM; Crotty S
    Curr Opin Immunol; 2017 Aug; 47():64-69. PubMed ID: 28738289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
    Kwong PD; Mascola JR; Nabel GJ
    Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007278. PubMed ID: 22229123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline-targeting immunogens.
    Stamatatos L; Pancera M; McGuire AT
    Immunol Rev; 2017 Jan; 275(1):203-216. PubMed ID: 28133796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in HIV-1 vaccine development.
    Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
    J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.